Condition

HCC clinical trials and research

• 27Clinical trials
• 21Countries

Newest HCC clinical trials

All recruiting trials (27)

• Personalized Neoantigen Vaccine Plus IL-12 in High-Risk Hepatocellular Carcinoma

  This study tests a personalized DNA vaccine plus IL-12 to see if it helps people who have high-risk liver cancer after tumor removal.

  Recruiting at 4 sites Phase 2 Geneos Therapeutics · Atlanta, Georgia and 8 other locations · NCT07722741

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Y-90 microspheres with camrelizumab and/or apatinib versus Y-90 alone or cTACE for unresectable liver cancer

  This trial will test whether adding camrelizumab and/or apatinib to Y-90 microsphere treatment helps people with unresectable, non-metastatic hepatocellular carcinoma more than Y-90 alone or conventional TACE.

  Recruiting at 2 sites Phase 2 GrandPharma (China) Co., Ltd. · Beijing and 2 other locations · NCT07334483

• How genes and alcohol interact to affect liver cancer risk

  This project will test if certain gene variants together with alcohol use and metabolic problems raise the risk of liver cancer in people with fatty or cryptogenic liver disease, especially men with diabetes or obesity.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan, Milano · NCT07272200

• MRI-guided adaptive single-session radiation for liver tumors (SABR)

  This trial will test a single-session, MRI-guided adaptive high-dose radiation (SABR) for adults with primary or metastatic liver tumors to see if on-table MRI planning and replanning can treat tumors without a separate simulation visit.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07223307

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

• QL1706 (iparomlimab + tuvonralimab) with TACE and lenvatinib for second-line treatment of unresectable intermediate-to-advanced liver cancer

  This test will try whether adding QL1706 (iparomlimab plus tuvonralimab) to TACE and lenvatinib helps people with unresectable intermediate-to-advanced hepatocellular carcinoma who progressed after PD-1/PD-L1 plus bevacizumab.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07099274

• Treatment for liver cancer at high risk of returning

  This study is testing a new treatment called AK112 to see if it can help people with liver cancer who are at high risk of their cancer coming back after surgery.

  Recruiting Phase 4 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT06930573

• Combining sintilimab, lenvatinib, and HAIC for treating borderline resectable liver cancer before surgery

  This study is testing if a combination of three treatments can help people with borderline resectable liver cancer do better in surgery compared to having surgery right away.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06904014

• Treatment of advanced liver cancer using a targeted T cell injection

  This study is testing a new type of T cell injection to see if it can safely help people with advanced liver cancer that has a specific marker called GPC3.

  Recruiting Phase 1 Peking University · Beijing, Beijing Municipality and 1 other locations · NCT06891742

• Comparing two treatments for intermediate-stage liver cancer

  This study is testing if a new treatment called TATE is better and safer than the standard treatment cTACE for people with intermediate-stage liver cancer.

  Recruiting at 2 sites Phase 2/3 Zhejiang Raygene Pharmaceuticals Co., Ltd · Nanjing, Jiangsu and 1 other locations · NCT06844357

• Stereotactic body radiotherapy with atezolizumab and bevacizumab for HCC with major portal vein thrombosis

  This test tries adding SBRT to atezolizumab plus bevacizumab to see if it helps people with HCC and major portal vein thrombosis who have not progressed after two cycles of systemic therapy.

  Recruiting at 2 sites Phase 2 Chinese University of Hong Kong · Hong Kong and 1 other locations · NCT06823375

• Combination therapy for advanced solid tumors

  This study is testing a new combination treatment for people with advanced solid tumors, including triple-negative breast cancer and liver cancer, to see if it works better after other treatments have not helped.

  Recruiting Phase 1 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Shanghai, Shanghai Municipality · NCT06764836

• HCC Liver-Link program to reduce racial gaps in liver cancer care

  This pilot will test whether the HCC Liver-Link program helps Black patients with early-stage HCC get faster curative treatment (transplant or resection) and better knowledge about their disease.

  Recruiting at 2 sites Indiana University · Indianapolis, Indiana and 1 other locations · NCT06728293

• HOPE perfusion to reduce liver cancer coming back after transplant

  This trial tests whether treating donor livers with hypothermic oxygenated perfusion (HOPE) before transplant helps people with hepatocellular carcinoma (HCC) have less cancer recurrence and better survival.

  Recruiting at 10 sites Phase 4 Clarunis - Universitäres Bauchzentrum Basel · New York, New York and 36 other locations · NCT06717919

• Using CAR-T cells to prevent recurrence of liver cancer after surgery

  This study tests if using CAR-T cells can help prevent liver cancer from coming back after surgery in patients at risk for recurrence.

  Recruiting at 15 sites Phase 1 CARsgen Therapeutics Co., Ltd. · Beijing and 14 other locations · NCT06560827

• Evaluating the risk of liver cancer in patients with fatty liver disease

  This study is testing how fatty liver disease might lead to liver cancer by looking at genetic and metabolic factors in patients with this condition.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan, Milano · NCT06523179

• Using SBRT for patients with limited progression of liver cancer on immunotherapy

  This study is testing if adding a special type of radiation therapy can help people with liver cancer who have a few growing spots while on immunotherapy feel better and live longer.

  Recruiting Chinese University of Hong Kong · Hong Kong · NCT06434480

• Neoadjuvant therapy for patients with resectable hepatocellular carcinoma using deep learning.

  This study is testing a new treatment plan using a combination of chemotherapy and other medications for patients with early-stage liver cancer to see if it helps them live longer and reduces the chances of the cancer coming back after surgery.

  Recruiting at 2 sites Phase 2 Tongji Hospital · Xiangyang, Hubei and 1 other locations · NCT06420440

• Comparing triple and dual therapies after liver surgery for liver cancer

  This study is testing if a combination of three treatments after liver surgery can help people with liver cancer do better and have fewer chances of the cancer coming back compared to just using two treatments.

  Recruiting Phase 4 Tongji Hospital · Wuhan, Hubei · NCT06311942

• Targeted therapy after surgery for liver cancer

  This study is testing if a combination of two drugs can help patients with a specific type of liver cancer who are at high risk of their cancer coming back after surgery.

  Recruiting Phase 4 Tongji Hospital · Wuhan, Hubei · NCT06311929

• Comparing ultrasound and MRI for liver cancer detection

  This study is trying to see if a special ultrasound or a quicker MRI is better at finding early liver cancer in people with uncertain liver nodules.

  Recruiting at 2 sites University of Texas Southwestern Medical Center · Ann Arbor, Michigan and 1 other locations · NCT06184152

• FOG-001 treatment for advanced or metastatic solid tumors

  This study is testing a new drug called FOG-001 to see if it can help people with advanced solid tumors, especially those with certain genetic changes, when traditional treatments aren't working.

  Recruiting at 32 sites Phase 1/2 Parabilis Medicines, Inc. · Phoenix, Arizona and 32 other locations · NCT05919264

• Testing a new drug for advanced solid tumors and lymphoma

  This study is testing a new drug called BPI-371153 to see if it is safe and effective for people with advanced solid tumors or lymphoma that hasn’t responded to other treatments.

  Recruiting at 3 sites Phase 1 Betta Pharmaceuticals Co., Ltd. · Chaoyang, Beijing Municipality and 3 other locations · NCT05341557

• Blood test for detecting liver cancer and cirrhosis

  This study is testing a new blood test to see if it can help detect liver cancer and cirrhosis in people who have or are being checked for liver issues.

  Recruiting at 7 sites Helio Genomics · Escondido, California and 6 other locations · NCT05199259

• Combining cabozantinib with ipilimumab/nivolumab and TACE for liver cancer treatment

  This study is testing if combining cabozantinib with two immune therapies and a specific type of chemo can help people with liver cancer who can’t have surgery feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT04472767

• Comparing MRI and Ultrasound for Liver Cancer Surveillance in Cirrhotic Patients

  This study is testing whether a new type of MRI can find liver cancer better than regular ultrasound in cirrhotic patients who have trouble with ultrasound imaging.

  Recruiting Concord Repatriation General Hospital · Camperdown, New South Wales and 9 other locations · NCT04455932

Related topics

Quick answers

How many HCC clinical trials are recruiting right now?

27, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in China (13 trials), United States (9 trials), Italy (3 trials), Australia (2 trials), New Zealand (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 9, Phase 4: 4, Phase 1: 4, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →